Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05420766

Impact of Sleep Duration on Immune Balance in Urban Children With Asthma

Urban children with asthma are at high risk for short sleep, due to an environment that jeopardizes both sleep and asthma management. Further, urban children with asthma suffer from altered immune balance, a key biological process contributing to individual differences in asthma morbidity and sleep health. In the proposed research, the researchers will examine the effects of shortened and recovery sleep on immune balance and associated changes in lung function in urban children with allergic asthma through an experimental design.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Urban children with asthma are at high risk for short sleep, due to an environment that jeopardizes sleep and asthma management. Further, this group suffers from altered immune balance, a key biological process contributing to individual differences in asthma morbidity and sleep health. Allergic asthma is a chronic inflammatory disorder driven primarily by disturbed T helper 1 (Th1)/ 2 (Th2) cytokine balance marked by Th2 cytokine (IL-4, IL-5 and/or IL-13) predominance. Experimental findings in healthy adults show that shortened sleep increases inflammatory cytokine (e.g., IL-6) and certain Th2 cytokine levels and that recovery sleep following sleep restriction promotes a return to immune balance. Whether sleep duration plays a key role in immune function and associated asthma activity in urban children with asthma remains a scientific gap. The researchers use an experimental design that targets sleep duration, because (1) the urban environment and asthma symptoms interact to shorten sleep, (2) sleep duration is a modifiable behavior overlooked in clinical care of urban children with asthma, and (3) experimental data are critical to test a causal link for sleep duration as a mechanism underlying immune balance and asthma.

The research team will enroll urban children (N=204; ages 7-11 years) with persistent allergic asthma and adequate sleep duration (9-11 h) who will complete a 4-week within-subjects protocol that includes 3 scheduled experimental sleep conditions: (1) 1 week stabilized sleep (individualized; 9-11 h time in bed), (2) 1 week shortened sleep (1.5 h decrease in time in bed), and (3) 2 weeks recovery sleep (1.5 h increase in time in bed). Sleep duration (actigraphy) and lung function (home spirometry) will be monitored daily and assess immune biomarkers weekly and at the midpoint of shortened sleep. To control time-in-study effects, 1/3 of the sample will receive only the stabilized sleep schedule across the 4-week protocol. In this project, the researchers will study only urban children with allergic asthma who obtain sufficient sleep (9-11 h, within national guidelines). The shortened sleep protocol will model the sleep loss that urban children with asthma can experience due to asthma and/or urban context. Additionally, the recovery sleep protocol simulates a sleep optimization intervention following shortened sleep in a well-controlled approach.

The first aim of the study is to examine the effects of shortened sleep on immune balance [e.g., Th1 (Interferon-IFN gamma)/Th2 (Interleukin-IL-4, IL-5, IL-13)R and plasma IL-6 levels]. The second aim involves determining the effects of recovery sleep on immune balance. The third aim involves examining the extent to which changes in immune balance are associated with changes in asthma-related lung function (changes in FEV1) under conditions of shortened and recovery sleep. Results from this study ultimately will support the development feasible, ecologically valid, and clinically meaningful interventions to optimize sleep duration, immune balance, and asthma in this at-risk group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Children 7-11 years old
  • Has physician-diagnosed asthma, per parent and pediatrician report
  • Meets criteria for current persistent asthma with a current prescription for an asthma controller medicine
  • Obtains 9.0-11.0 h of sleep per 24 h day in the past month
  • Has a positive allergy skin test performed at the clinic visit
  • Resides and attend school in one of the targeted urban areas (Rhode Island: East Providence, North Providence, Providence, Warwick, Cranston, Woonsocket, Central Falls, Pawtucket, Lincoln, Johnston. Massachusetts: Attleboro, North Attleboro, Fall River.
  • Has a primary caregiver who speaks English

Exclusion:

  • No asthma diagnosis
  • No use of asthma controller medication
  • Severe persistent asthma that is poorly controlled
  • Diagnosis of additional pulmonary disease or medical condition or immune deficiency disorders
  • Use of systemic steroids <30 days of screening
  • Asthma-related emergency department visit and/or asthma-related hospitalization in past 90 days
  • Marked developmental delay, psychiatric conditions, academic/behavioral problems, learning disabilities
  • Tanner stage 3-5 of pubertal development
  • Diagnosed ADHD; Use of stimulants to treat ADHD
  • An Apnea-Hypoxia Index >5 (indicator of sleep disordered breathing)

Treatment and study plan

Shortened Sleep

Behavioral

In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.

Stabilized sleep

Behavioral

In this control condition, children go to bed at their usual time throughout the 4-week protocol.

Primary outcomes

  1. 10mL of heparinized blood

    Time frame: Changes in immune function across Days 7, 11, 14, 21 and 28 of the 4-week sleep protocol

    Changes in the immune biomarker profile related to lung function and asthma morbidity: CD4+IFNy+ Th1 cells; CD4+IL4+, CD4+IL5+, CD4+IL13+ Th2 cells; plasma IL-6

Secondary outcomes

  1. Forced Expiratory Flow in 1 second (FEV1) % predicted

    Time frame: Lung function over the 4-week sleep protocol

    Asthma-related lung function

Other outcomes

  1. Time in Bed actigraphy scores

    Time frame: Continuously throughout the 4-week sleep protocol

    Sleep Duration measured via actigraphy, to validate the prescribed sleep schedules

Study contacts

Contact information is provided by the study sponsor or research team.

Daphne Koinis-Mitchell, PhD

CONTACT

[email protected]

401-793-8632

Sheryl J Kopel, MSc

CONTACT

[email protected]

401 444-7217

Sponsors and collaborators

Lead sponsor

Rhode Island Hospital

Other

Collaborators

  • Brown University
  • University of Mississippi Medical Center

Registry information

Acronym: AIMS

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jun 15, 2022
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.